Clinical trials: Yellow Fever
HIV Infection, Yellow Fever
The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.
Main objective : To develop the tools for evaluation of humoral and cell-mediated immunity after Yellow Fever Vaccine (YFV) and compare virological and immune responses in HIV-positive and HIV-negative individuals who had not…
- Trial name
- EP46 NOVAA (NCT01426243)
- Testing
- Yellow fever vaccination (STAMARIL)
- Where
- France
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Vaccine Response Impaired
Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines
This study evaluates seroconversion against measles, mumps, rubella and yellow fever following vaccination. One-third of children will receive both yellow fever and measles, mumps, and rubella (MMR) vaccines on the same day; one…
- Trial name
- NCT03368495
- Testing
- Co-administration of MMR/YF, MMR followed by YF, YF followed by MMR
- Where
- 4 sites in Argentina
- Volunteers
- 851 people, healthy volunteers welcome
- Sponsor
- Alba Maria Ropero
Ebola Virus Disease, Malaria
Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC
A mobile suitcase laboratory for EBOV point-of-care (POC) detection at Ebola treatment centers was successfully implemented in Guinea during the large Ebola virus disease (EVD) outbreak in West-Africa 2014-2015.
- Conditions
- Ebola Virus Disease, Malaria, Typhoid Fever, Dengue Fever
- Trial name
- MobEboDRC (NCT04235361)
- Testing
- Differential RPA tests
- Where
- 4 sites in Canada, Democratic Republic of the Congo and 2 more
- Volunteers
- 500 people
- Sponsor
- University of Stirling
Yellow Fever
A Pilot Study to Finetune Skin Processing Procedures in Recent Vaccinees, Prior to GeKoSkimm Study Initiation (GeKoSkimm-pilot)
This pilot study aims to optimize the sample processing techniques for collecting and analyzing skin biopsies obtained from individuals routinely vaccinated against yellow fever.
- Trial name
- NCT06539351
- Testing
- Skin biopsy
- Where
- Belgium
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Treatment of Acute Yellow Fever Virus Infection
Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans
Yellow Fever is an acute viral hemorrhagic disease caused by the Yellow Fever Virus (YFV), a re-emerging arbovirus transmitted by the same mosquito vector (Aedes aegypti) that transmits Dengue virus (DENV) and Zika virus (ZIKV).
- Trial name
- NCT03776786
- Testing
- TY014, 0.9% Saline
- Where
- Singapore
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Tysana Pte Ltd
Japanese Encephalitis, Yellow Fever
Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)
The purpose of this study is to obtain safety, tolerability, and immunogenicity data on the co-administration or sequential administration of Chimeravax™-JE vaccine and STAMARIL®.
- Trial name
- NCT00982137
- Testing
- Live attenuated Japanese encephalitis virus; Yellow fever virus, Yellow fever virus; Live attenuated Japanese encephalitis virus
- Where
- Australia
- Volunteers
- 108 people
- Sponsor
- Sanofi
Yellow Fever
Phase 3 Single Arm, Open Study on vYF in Adults
The purpose of this study is to assess the safety and immunogenicity of vYF in adults aged 18 years and over in Japan. Study details include: The study duration will be up to approximately 1 month.
- Trial name
- NCT07222059
- Testing
- Yellow fever vaccine (live)
- Where
- 4 sites in Japan
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Yellow Fever
Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children
In a previous study by the researchers' group, the researchers' investigate the duration of yellow fever post-vaccination immunity in vaccinated children between 9 and 23 months of age.
- Trial name
- NCT02990182
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Viremia
Yellow Fever Virus Vaccine and Immune Globulin Study
The purpose of this study is to determine whether immune globulin can limit the amount of yellow fever vaccine virus present in the blood after vaccination without compromising the immunity associated with the yellow fever…
- Trial name
- NCT00254826
- Testing
- YF-VAX® plus saline, 17D YF Vaccine plus Ig,
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Emory University
Yellow Fever Immunization
A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population
The purpose of this study is to determine whether vYF (investigational vaccine) is safe and can help the body to develop antibodies (immunogenicity) compared with Stamaril vaccine and YF-VAX vaccine (both licensed vaccines) and…
- Trial name
- NCT07103148
- Testing
- Yellow fever vaccine (live), Measles, combinations with mumps and rubella, live attenuated
- Where
- 15 sites in Honduras, Mexico and 1 more
- Volunteers
- 2,440 people, healthy volunteers welcome
- Sponsor
- Sanofi
Immunization, Infections
Description of the Immune Response to Yellow Fever Vaccination
Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from…
- Trial name
- IVORY2 (NCT06718127)
- Testing
- blood samples collection
- Where
- France
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Yellow Fever, Rabies
A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of AVX70120 and of AVX70481 in healthy participants.
- Trial name
- SAFYR (NCT06998004)
- Testing
- AVX70120 low dose level, AVX70120 middle dose level, AVX70120 high dose level
- Where
- 2 sites in Belgium
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- AstriVax Therapeutics
Yellow Fever Vaccine
Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military
Yellow fever is an acute viral disease transmitted by mosquitoes in South America, Central America and Africa. It is more prevalente in males gender and the age above 15 years due to the greater exposure in the wild endemic area…
- Trial name
- NCT03338231
- Where
- Brazil
- Volunteers
- 374 people
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
HIV Infections, Yellow Fever Vaccine
"Persistence of Neutralizing Antibodies Against Yellow Fever (YF) in HIV-infected Patients"
Participating countries: Belgium Context: In June 2013, WHO notified that "a single dose of YF vaccine is sufficient to confer sustained life-long protective immunity against YF disease and that a booster dose is not necessary".
- Trial name
- NCT03591003
- Testing
- Yellow fever neutralizing antibodies measure
- Where
- 12 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Yellow Fever Vaccine
Characterization of Human Memory Immune Responses to Prior Yellow Fever Vaccination
The objective of this study is to study immune memory generated against the yellow fever (YFV) vaccine in participants who have previously received the vaccine.
- Trial name
- NCT01244802
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Emory University
Vaccination
The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination
This study aims to investigate the effect of providing additional information about possible mild side effects of the yellow fever vaccination on the reporting of physical symptoms.
- Trial name
- NCT00708630
- Testing
- Extended information on side effects
- Where
- New Zealand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Auckland, New Zealand
Yellow Fever
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
The study is designed as a Phase III, double-blind, multicenter, randomized, active-controlled, parallel-group design in which two groups of participants will receive either SII-YFV or STAMARIL® - a licensed and WHO pre-qualified…
- Trial name
- NCT05421611
- Testing
- STAMARIL, SII-YFV
- Where
- 2 sites in Kenya
- Volunteers
- 1,824 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Tuberculosis, Diphtheria
Evaluation of an Infant Immunization Encouragement Program in Nigeria
Previous studies have shown that a small incentive can have a large impact on health behaviors like vaccinating children. New Incentives, an international non-governmental organization (NGO), aims to boost demand for immunization…
- Conditions
- Tuberculosis, Diphtheria, Tetanus, Pertussis
- Trial name
- NCT03870061
- Testing
- All Babies Are Equal Initiative (conditional cash transfer program)
- Where
- 3 sites in Nigeria
- Volunteers
- 5,187 people, healthy volunteers welcome
- Sponsor
- GiveWell
Yellow Fever Vaccine, Immunity
Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)
The study main objective is to assess the immune status of children and adults who have never vaccinated, they will receive the first dose of 17DD yellow fever vaccine provided by the study and will be monitored for 10 years.
- Trial name
- NCT02555072
- Testing
- yellow fever vaccine
- Where
- 6 sites in Brazil
- Volunteers
- 4,761 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)